A
1.22
0.01 (0.41%)
| Penutupan Terdahulu | 1.21 |
| Buka | 1.21 |
| Jumlah Dagangan | 7,299,575 |
| Purata Dagangan (3B) | 5,860,164 |
| Modal Pasaran | 419,771,424 |
| Harga / Jualan (P/S) | 91.86 |
| Harga / Buku (P/B) | 1.33 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2026 |
| EPS Cair (TTM) | -1.22 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -100.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 23.07% |
| Nisbah Semasa (MRQ) | 9.71 |
| Aliran Tunai Operasi (OCF TTM) | -197.33 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -96.65 M |
| Pulangan Atas Aset (ROA TTM) | -28.92% |
| Pulangan Atas Ekuiti (ROE TTM) | -59.60% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Allogene Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
0.1
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| Persekitaran Makro | 0.0 |
| AI Insight | NA |
| Purata | 0.13 |
|
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 17.70% |
| % Dimiliki oleh Institusi | 81.75% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |